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at post-treatment Week 12 (SVR12). The primary safety endpoint was haemoglobin <10 g/dL during treatment and decreased from baseline. Overall, 105 patients enrolled. The SVR12 rate was 89.5% (n/N = 94/105; 95% CI, 83.7-95.4). The study did not achieve noninferiority versus the historic SVR12 rate for OBV/PTV/r + DSV plus weight-based ribavirin. Five patients experienced virologic failure, four discontinued, and two had missing SVR12 data. Excluding nonvirologic failures, the SVR12 rate was 94.9% (n/N = 94/99). One patient met the primary safety endpoint. OBV/ PTV/r + DSV plus low-dose ribavirin offers an alternative option for patients in whom
| INTRODUC TI ON
Ribavirin remains a component of several direct-acting antiviral (DAA) regimens currently recommended for treating chronic hepatitis C virus (HCV) infection. 1 If indicated, ribavirin is administered daily in two divided doses based on body weight (1000 mg for <75 kg; 1200 mg for ≥75 kg), with appropriate dose reductions in patients with renal dysfunction. 2 However, ribavirin treatment can be associated with increased rates of adverse events (AEs), especially anaemia, which may necessitate ribavirin dose reductions or discontinuation that can potentially lower sustained virologic response at post-treatment Week 12 (SVR12).
3
Treatment with ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) with and without full-dose ribavirin for 12 weeks achieved SVR12 rates of 97% and 90%, respectively, in genotype (GT)1a-infected patients without cirrhosis. 4 The lower SVR12 rate in the ribavirin-free arm was attributed to a higher virologic failure rate versus full-dose ribavirin (7.8% vs 2.0%), mostly due to virologic relapse (5.2% vs 1.0%). 4 Although ribavirin-related AEs and laboratory abnormalities were more frequent with full-dose ribavirin, discontinuation rates were low with either regimen.
The GEODE-II study evaluated the safety and efficacy of OBV/ PTV/r + DSV coadministered with low-dose ribavirin for 12 weeks in GT1a-infected patients without cirrhosis who were either HCV treatment-naïve or had prior interferon-based treatment experience. Efficacy and safety analyses were performed on all patients who received ≥1 dose of study drug (intention-to-treat [ITT] population).
| ME THODS
SVR12 was also analysed in the modified ITT (mITT) population, which excluded nonvirologic failures. For SVR12 rates, two-sided 95% confidence intervals (CIs) were calculated using the normal approximation to the binomial distribution. Noninferiority of OBV/PTV/r + DSV plus lowdose ribavirin against the historical threshold 4 for OBV/PTV/r + DSV plus weight-based ribavirin was achieved if the 95% CI lower bound for SVR12 was >92%. SVR12 rates in the presence or absence of baseline polymorphisms were compared using Fisher's exact test.
The study protocol was approved by the independent ethics committee or institutional review board at each study centre and conducted in accordance with the Good Clinical Practice guidelines and the ethical principles of the Declaration of Helsinki. All patients provided written informed consent.
| RE SULTS
A total of 105 patients enrolled from 10 sites in the United States; all received ≥1 study drug dose. Ninety-nine patients completed treatment and six discontinued treatment prematurely (primary reasons: AE, n = 1; loss to follow-up [LTFU], n = 1; noncompliance, n = 1; other, n = 3 [patient decision, incarceration, hospitalisation]). Ninety-seven patients completed the study and eight discontinued, six of whom were LTFU. No patients switched to full-dose ribavirin.
Most patients were white (85.7%), female (52.4%), HCV treatment-naïve (88.6%) and had minimal fibrosis (F0-F1, 81.0%). High percentages of patients reported a history of drug abuse or prior use of behavioural mood-modifying drugs (76.2%) or a history of alcoholism (81.0%) (Table S1) .
By ITT analysis, 89.5% of patients achieved SVR12 (n/N = 94/105; 95% CI, 83.7-95.4). The lower bound 95% CI was <92%. One patient full-dose ribavirin may compromise tolerability, although noninferiority to the weightbased ribavirin regimen was not met.
K E Y W O R D S
genotype 1a, GEODE-II, hepatitis C virus, interferon-free therapy, low-dose ribavirin had on-treatment virologic failure and four had post-treatment relapse. Six patients had nonvirologic failure (four discontinued treatment prematurely; two had missing SVR12 data). By mITT analysis, 94.9% achieved SVR12 (n/N = 94/99; 95% CI, 90.6-99.3). SVR12
rates for subgroups are provided in Table S2 . One patient relapsed during the 24-week post-treatment period.
Overall, 73.3% of patients experienced ≥1 treatment-emergent AE ( One patient (1%) experienced haemoglobin <10 g/dL and decreased from baseline during treatment and required ribavirin dose interruption and modification to 400 mg; this patient experienced on-treatment virologic failure. Another patient experienced an AE of decreased haemoglobin leading to ribavirin dose modification; this patient achieved SVR12.
The respective prevalence of NS3-Q80K and OBV-specific baseline polymorphisms was 46.5% and 11.5% ( Figure S1 ). The SVR12 rate (57.1%, 4/7) in patients with NS3-Q80K and OBVspecific polymorphisms in NS5A was lower than in patients without NS3-Q80K or OBV-specific polymorphisms (100%, 47/47; P = 0.001). SVR12 rates with OBV-specific baseline polymorphisms alone (100%, 4/4) or NS3-Q80K alone (94.7%, 36/38)
were not different from the overall SVR12 rate (94.8%, 91/96), or the rate in patients without OBV-specific polymorphisms or NS3-Q80K (100%, 47/47). PTV-and DSV-specific baseline polymorphisms were rare (no impact on SVR12). Treatment-emergent substitutions were detected among the six virologic failures (Table   S3 ).
Trough plasma concentrations of study drugs were generally comparable to C trough values observed in similar studies where weight-based ribavirin was administered (AbbVie data on file), whereas low-dose ribavirin values were approximately 50% lower (Table S4 ).
| D ISCUSS I ON
Low-dose, once-daily ribavirin may be administered to certain patients because of tolerability concerns. 1, 5 A once-daily regimen may also improve treatment compliance. 6 In GEODE-II, we evaluated OBV/PTV/r + DSV plus low-dose 600-mg ribavirin for patients with GT1a infection. The SVR12 rate was 89.5% (ITT analysis), and noninferiority was not achieved versus OBV/PTV/r + DSV plus full-dose ribavirin. 4 The SVR12 rate was 94.9% by mITT analysis, demonstrating good efficacy in patients who completed 12-weeks treatment.
Six patients failed to achieve SVR12 because of premature treatment discontinuation or missing SVR12 data. The high prevalence of patients with a history of psychosocial disorders may have accounted for the high rate of nonvirologic failures.
The presence of OBV-specific baseline polymorphisms in combination with NS3-Q80K was associated with low SVR12 rates (57.1%), suggesting a role for baseline resistance testing. However, the number of patients who had this combination was low (n = 7), limiting the interpretation of this finding. AEs, adverse events; DAAs, direct-acting antivirals; ULN, upper limit of normal. a One case each of bipolar 1 disorder, psychotic disorder and cyclic vomiting syndrome. One serious AE had a reasonable possibility of being related to the study drug (bipolar 1 disorder). b One patient with a history of bronchial asthma had nonserious AEs that had a reasonable possibility of being related to the study drug (chest pain, increased heart rate and dyspnoea), and one patient had a recurrent psychotic episode. c Decreases in haemoglobin that led to ribavirin dose modification (adjusted to 400 mg daily). d For laboratory abnormalities, N = 104.
The safety profile of this regimen was consistent with that observed in pivotal studies. 4, 7, 8 Ribavirin exposures were approximately 50% lower than in historical controls receiving full-dose ribavirin. This could explain the favourable improvements in ribavirin-related laboratory abnormalities and dose modifications versus other studies. 
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